Volume 16.02 | Jan 19

Issue 16.02 January 19, 2015
Cell Therapy News - Your Industry in an Instant
Your Industry in an Instant Twitter   Facebook  
Publications | Reviews | Science | Policy | Business | NIH | CBER | Regulatory | Events | Jobs
Bone Stem Cells Shown to Regenerate Bones, Cartilage in Adult Mice
A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. The cells, called osteochondroreticular (OCR) stem cells, were discovered by tracking a protein expressed by the cells. Using this marker, the researchers found that OCR cells self-renew and generate key bone and cartilage cells, including osteoblasts and chondrocytes. [Press release from the Columbia University Medical Center discussing online publication in Cell] Press Release | Abstract | Graphical Abstract | Video
Free Wallchart: Small Molecules, Big Impact in PSC Research
PUBLICATIONS (Ranked by impact factor of the journal)
Anticancer Immunotherapy by CTLA-4 Blockade: Obligatory Contribution of IL-2 Receptors and Negative Prognostic Impact of Soluble CD25
Scientists show that neutralization of IL-2 or blocking the α and β subunits of the IL-2 receptor (CD25 and CD122, respectively) abolished the antitumor effects and the accompanying improvement of the ratio of intratumoral T effector versus regulatory cells, which were otherwise induced by cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade in preclinical mouse models. [Cell Res] Full Article

Enrichment of Human Hematopoietic Stem/Progenitor Cells Facilitates Transduction for Stem Cell Gene Therapy
CD34+/CD38 cells were isolated from healthy cord blood CD34+ cells by fluorescence activated cell sorting and transduced with a lentiviral vector expressing an anti-sickling form of beta-globin. In vivo studies showed engraftment of transduced CD34+/CD38 cells when transplanted in competition with 100-fold more CD34+/CD38+ cells. [Stem Cells] Abstract

Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy (X-ALD)
Scientists used recombinant adeno-associated virus serotype 9 (rAAV9) vector for delivery of the human ATP-binding cassette transporter gene (ABCD1) to mouse central nervous system (CNS). In vivo, AAV9-ABCD1 was delivered to Abcd1-/- mouse CNS by either stereotactic intracerebroventricular or intravenous injections. [Mol Ther] Abstract

Triazine-Modified Dendrimer for Efficient TRAIL Gene Therapy in Osteosarcoma
A triazine-modified dendrimer G5-DAT66 was synthesized and used as a vector for tumor necrosis factor related apoptosis inducing ligand (TRAIL) gene therapy in vitro and in vivo. In vivo studies prove that G5-DAT66 efficiently transfects TRAIL plasmid in tumors and inhibits tumor growth in osteosarcoma-bearing mice. [Acta Biomater] Abstract

Evaluation of In Vivo Antitumor Effects of ANT2 shRNA Delivered Using PEI and Ultrasound with Microbubbles
To evaluate the antitumor effects of adenine nucleotide translocase-2 (ANT2) short hairpin RNA (shRNA) by intraperitoneal injection using the polyethylenimine (PEI) and an ultrasound gene delivery method, human breast carcinoma MDA-MB-231 cells were injected subcutaneously into NOD/Shi-scid/IL-2Rγnull mice. [Gene Ther] Abstract

Sendai Virus-Mediated Gene Transfer of the c-Myc Suppressor Far-Upstream Element-Binding Protein-Interacting Repressor Suppresses Head and Neck Cancer
Using in vitro and in vivo xenograft mouse models, investigators observed efficient expression of green fluorescent protein (GFP) following transduction with the far-upstream element-binding protein-interacting repressor using fusion gene-deleted Sendai virus vector encoding GFP into head and neck squamous cell carcinoma cells. [Gene Ther] Abstract

Secretomes from Bone Marrow-Derived Mesenchymal Stromal Cells Enhance Periodontal Tissue Regeneration
Low survival rates and the potential tumorigenicity of implanted mesenchymal stromal cells (MSCs) could undermine the efficacy of cell-based therapy. The use of conditioned media from MSCs (MSC-CM) may be a feasible approach to overcome these limitations. Researchers aimed to confirm the effect of MSC-CM on periodontal regeneration. [Cytotherapy] Abstract

Stable Knockdown of LRG1 by RNA Interference Inhibits Growth and Promotes Apoptosis of Glioblastoma Cells In Vitro and In Vivo
Scientists further demonstrate that the silencing of leucine-rich α2 glycoprotein 1 (LRG1) expression effectively reduced the tumorigenicity of U251 cells, delayed tumor formation, and promoted apoptosis in a xenograft tumor model in vivo. [Tumour Biol] Abstract

Prolonged Clinical Remissions in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Autologous Stem Cell Transplantation Incorporating Rituximab
Three sequential Phase II trials were conducted with different immunotherapy approaches to enhance the outcome of autologous transplant (high-dose therapy and autologous stem cell transplantation) for recurrent follicular lymphoma. [Ann Hematol] Abstract

Learn More: StemSpan™ Myeloid Expansion Supplement
Respiratory Tissue Engineering: Current Status and Opportunities for the Future
The authors focus on the different biomaterials and tissue engineered systems employed in upper and lower respiratory tract engineering, and give a final perspective of the opportunities and challenges facing the field of respiratory tissue engineering. [Tissue Eng Part B Rev] Abstract

Tailoring Bioengineered Scaffolds for Stem Cell Applications in Tissue Engineering and Regenerative Medicine
New insights into the biology of stem cells are expected to eventuate from advances in material science, in particular, from synthetic hydrogels that display physicochemical properties reminiscent of the natural cell microenvironment and that can be engineered to display or encode essential biological cues. [Stem Cells Transl Med] Abstract

Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field.

Request a Sample: ReproTeSR™
Phase II Clinical Data of Peregrine Pharmaceuticals’ Bavituximab in Combination with Sorafenib Presented
Peregrine Pharmaceuticals, Inc. announced the presentation of clinical data related to the company’s immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab. [Press release from Peregrine Pharmaceuticals, Inc. discussing research presented at American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, San Francisco] Press Release

OncoMed Presents Final Phase Ib Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic Cancer
OncoMed Pharmaceuticals, Inc. presented final safety, efficacy and biomarker data from the company’s Phase Ib ALPINE clinical trial of tarextumab in 40 patients with frontline metastatic pancreatic cancer. [Press release from OncoMed Pharmaceuticals, Inc. discussing research presented at American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, San Francisco] Press Release

Cell Culture World Congress 2015
Nature Owner Merges with Publishing Giant
Macmillan Science and Education, the London-based publisher of Nature and Scientific American, will merge with Berlin-based Springer Science+Business Media, one of the world’s largest science publishers. [Nature News] Editorial

Economists Offer New Arguments for U.S. Research Tax Break
The National Association of Manufacturers released a report from three academic economists that reviews the scholarly literature on the economic impact of the so-called R&D tax credit, worth some $7 billion annually in recent years. [ScienceInsider] Editorial | Report

A One-Grant Limit: NIH Institute Puts Squeeze on Flush Investigators
In the latest example of budget stretching at the National Institutes of Health (NIH), the agency’s basic science institute is imposing a strict one-grant limit on scientists who already have plentiful no-strings support. The move could free up at least $6 million, or 25 grants for other scientists. [ScienceInsider] Editorial

From our sponsor: Free Nature Reviews Immunology poster – Immune Response to HIV. Request a copy.
Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples
Human Longevity, Inc. announced a multi-year agreement with Genentech, a member of the Roche Group, to conduct whole genome sequencing of tens of thousands of de-identified samples from Genentech. [Human Longevity, Inc.] Press Release

Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome
Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen’s bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a “bridge” between T cells and cancer cells. [Amgen] Press Release

Kymab Partners with Cancer Immunotherapy Expert on Anti-Cancer Therapeutics
Kymab announced a collaboration with Dr. Stephen Gillies. Dr. Gillies is a pioneer in the field of cancer immunotherapy and inventor of immunocytokine platforms from which several molecules are currently in clinical development. [Kymab Limited] Press Release

Treeway Announces License and Collaboration Agreement with uniQure to Develop a Gene Therapy for Amyotrophic Lateral Sclerosis (ALS)
Treeway B.V. have announced a collaboration with uniQure N.V. to develop a gene therapy treatment for ALS. Under the terms of the licensing and collaboration agreement, uniQure has granted Treeway an exclusive license in this field to uniQure’s relevant AAV5 viral vector and glial cell-derived neurotrophic factor intellectual property. [Treeway B.V.] Press Release

Boehringer Ingelheim and Yale University Collaborate to Investigate Novel Immunotherapy Targets Across Several Therapeutic Areas
Boehringer Ingelheim announced a collaboration with Yale University with the goal of researching novel therapeutic targets in the field of immune-modulation. Under the terms of the agreement, the research capabilities of Boehringer Ingelheim and Yale University will be brought together to identify new immune-modulatory agents for oncology, autoimmune and respiratory disorders. [Boehringer Ingelheim GmbH] Press Release

Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact
Intrexon Corporation and its oncology partner, ZIOPHARM Oncology announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. [Intrexon Corporation] Press Release

Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate Adcetris and Bristol-Myers Squibb’s immunotherapy Opdivo in two planned Phase I/II clinical trials. [Bristol-Myers Squibb Company] Press Release

Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (Nivolumab) in Combination with Galunisertib in Advanced Solid Tumors
Bristol-Myers Squibb Company and Eli Lilly and Company announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo in combination with Lilly’s galunisertib. [Bristol-Myers Squibb Company] Press Release

Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company
Tekmira Pharmaceuticals Corporation and OnCore Biopharma, Inc. announced that they have agreed to merge to create a new leading global hepatitis B virus company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches. [Tekmira Pharmaceuticals Corporation] Press Release

Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIa Delayed-Union Trial
Bone Therapeutics announced positive efficacy results for the first cohort of four patients enrolled in the Phase I/IIa delayed-union trial with its allogeneic bone-forming cell product ALLOB®. [Bone Therapeutics] Press Release
Center for Scientific Review; Notice of Closed Meetings (FR Doc. No: 2015-00495)

Government-Owned Inventions; Availability for Licensing (FR Doc. No: 2015-00535)
2014 Biological Device Application Approvals
Food and Drug Administration (United States)

CHEMBIOMED, LTD., Opportunity for a Hearing on a Proposal To Revoke U.S. License No. 0916 (FR Doc. No: 2015-00442)

Study Data Technical Conformance Guide and Data Standards Catalog; Availability (FR Doc. No: 2015-00206)
NEW CIRM 2.0 Free Webinar – Changing the Way We Work
January 21, 2015 12:00 PM PST

NEW Cellular Therapy 2015 – 8th International Symposium on the Clinical Use of Cellular Products
March 19-20, 2015
Erlangen, Germany

NEW Cell Culture World Congress USA 2015
May 27-28, 2015
San Diego, United States

NEW 2nd International Congress on Stem Cell and Cellular Therapies (ICSCCT)
October 15-18, 2015
Antalya, Turkey

Visit our events page to see a complete list of events in the cell, gene and immunotherapy community.
NEW Director (California Institute for Regenerative Medicine)

NEW Postdoctoral Position – Immunology Animal Models (The Technical University of Denmark)

NEW Postdoctoral Position – Inflammatory Bowel Disease (The Technical University of Denmark)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Cell Therapy Manufacturing Scientist (SLS Services Ltd.)

Postdoctoral Fellowship – CNS Inflammation (Rutgers University)

Postdoctoral Fellow – Radiation Therapy and Immunotherapy (Georgia Regents University Cancer Center)

PhD Student – Experimental Leukemia Research (University Children’s Hospital Basel)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Scientist – Reprogramming and Pluripotent Stem Cell Biology (STEMCELL Technologies Inc.)

Scientist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Liver Cell Biology (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.